Related references
Note: Only part of the references are listed.Biomarkers in early clinical trials: The committed and the skeptics
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2008)
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative Cancer Therapies (MDICT)
Christopher M. Booth et al.
EUROPEAN JOURNAL OF CANCER (2008)
Dose selection in phase I studies: Why we should always go for the most effective
Ian E. Haines
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dose selection in phase I studies: Why we should always go for the top
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Challenges and pitfalls of combining targeted agents in phase I studies
Stephen A. Cannistra
JOURNAL OF CLINICAL ONCOLOGY (2008)
Risks and benefits associated with novel phase 1 oncology trial designs
Shlomo A. Koyfman et al.
CANCER (2007)
Ethics of phase 1 oncology studies - Reexamining the arguments and data
M Agrawal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer
DM Potter
STATISTICS IN MEDICINE (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
